Cullinan Oncology Secures $150 Million Series A Financing To Build Innovative Development Company

CAMBRIDGE, Mass., October 3, 2017 - - Cullinan Oncology, LLC announced today a $150 million Series A financing co-led by the UBS Oncology Impact Fund (OIF) managed by MPM Capital, a worldwide leader in oncology investing, and F2 Ventures.

October 3, 2017|Tags: |